2026-01-02 - Analysis Report
Okay, here's a comprehensive report on Merck & Co. Inc. (MRK), based on the data provided:

**1) Return Rate Comparison & Alpha/Beta Analysis**

*   **Company Overview:** Merck & Co. Inc. is a global pharmaceutical company focused on developing and marketing a wide range of medicines, vaccines, and animal health products.
*   **Cumulative Return:**
    *   MRK: 21.74%
    *   VOO (S&P 500): 105.07%
*   **Divergence:**
    *   Current Divergence: -83.3
    *   Relative Divergence: 21.7 (Meaning the current divergence is relatively low compared to its historical range)

**Alpha, Beta Analysis:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2016-2018  | 51.0% | 69.5% | 22.0% | 0.7 | 182.1 |
| 2017-2019  | 47.0% | 69.5% | 5.0% | 0.7 | 216.8 |
| 2018-2020  | 38.0% | 81.8% | 5.0% | 0.7 | 195.0 |
| 2019-2021  | 8.0% | 81.8% | -68.0% | 0.6 | 191.4 |
| 2020-2022  | 36.0% | 81.0% | 17.0% | 0.5 | 277.1 |
| 2021-2023  | 48.0% | 80.2% | 20.0% | 0.3 | 272.3 |
| 2022-2024  | 22.0% | 80.2% | -8.0% | 0.3 | 248.5 |
| 2023-2025  | -2.0% | 80.8% | -70.0% | 0.3 | 262.9 |

*   **Analysis:**
    *   **Underperformance:** MRK has significantly underperformed the S&P 500 over the period examined.
    *   **Alpha & Beta:** Beta values are consistently below 1, indicating lower volatility than the market. However, the Alpha values fluctuate significantly, even showing negative values in recent periods (2019-2021, 2022-2024, 2023-2025), indicating underperformance relative to the risk-free rate.
    *   **CAGR & MDD:** The CAGR (Compound Annual Growth Rate) has varied over the years, with a negative return in the most recent period (2023-2025). The MDD (Maximum Drawdown) is consistently high, showing significant potential for losses.

**2) Recent Stock Price Fluctuations**

*   **Current Price:** 105.26
*   **Previous Close:** 106.06
*   **Change:** -0.75
*   **5-day SMA:** 106.234
*   **20-day SMA:** 101.8025
*   **60-day SMA:** 94.1685

*   **Analysis:** The stock price has decreased slightly compared to the previous close.  The 5-day SMA is above the 20-day SMA, and the 20-day SMA is above the 60-day SMA. This *could* be interpreted as a short-term bullish signal, however the data isn't convincing enough to make a bullish call.

**3) RSI, PPO Index, & Divergence Analysis**

*   **MRI:** 0.9 (High Investment Recommended)
*   **RSI:** 75.92 (Overbought)
*   **PPO:** 0.1233
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (1 shares - Very Safe - MRI:0.90)
*   **Recent Relative Divergence Change:** 1.7 (+) (Short-term increase)
*   **Expected Return:** 0.0%

*   **Analysis:**
    *   **MRI:** While the MRI suggests high investment recommendation, it's crucial to consider other factors.
    *   **RSI:** The RSI indicates that the stock is currently overbought, suggesting a potential for a price correction.
    *   **PPO:** The PPO being positive can indicate a change in momentum, but it's very low.
    *   **Hybrid Signal:** The hybrid signal recommends 100% investment which seems to contradict the fact the the Expected Return is 0.0%.
    *   **Relative Divergence:** The increase in relative divergence suggests a short-term upward trend compared to the S&P 500.

**4) Recent News & Significant Events**

*   **Positive News:**
    *   Morgan Stanley lifted MRK's price target due to an improved biopharma outlook.
    *   Seeking Alpha published an article titled "Merck: Framework For Success".
    *   Forbes wrote an article titled "Why Is Merck Stock Surging?"

*   **Negative/Neutral News:**
    *   "Merck (MRK) stock slips into 2026 as New Year holiday shuts U.S. markets — what investors watch next" is simply a new year/market close rehash.
    *   Northwest Capital Management Inc sold shares of MRK.
    *   Trefis analyzed how MRK stacks up against its peers (requires further investigation to determine the conclusion).

*   **Analysis:**  The news is mixed.  The positive news (price target increase, "Framework for Success," "Why is Merck Stock Surging?") suggests analyst and investor optimism, while the share sale and peer comparison introduce some caution.

**4-2) Analyst Opinions**

*   **Consensus:** Buy
*   **Mean Rating:** 1.90 (~Buy)
*   **Opinions:** 26
*   **Target Price (avg/high/low):** 110.04 / 139.00 / 83.00

*   **Analysis:** Analyst consensus is generally positive with a "Buy" rating and an average target price of $110.04, suggesting potential upside.

**5) Recent Earnings Analysis**

| 날짜         | EPS   | 매출        |
|--------------|-------|-------------|
| 2025-11-05  | 2.32  | 17.28 B$    |
| 2025-08-05  | 1.76  | 15.81 B$    |
| 2025-05-02  | 2.01  | 15.53 B$    |
| 2024-11-06  | 1.25  | 16.66 B$    |
| 2025-11-05  | 1.25  | 16.66 B$    |

*   **Analysis:**  Earnings Per Share (EPS) has been volatile, improving after 2024-11-06. Revenue has also shown growth in the most recent quarters.

**6) Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-09-30  | $17.28B   | 77.69%        |
| 2025-06-30  | $15.81B   | 77.50%        |
| 2025-03-31  | $15.53B   | 77.98%        |
| 2024-12-31  | $15.62B   | 75.50%        |
| 2024-09-30  | $16.66B   | 75.51%        |

**Capital and Profitability:**

| Quarter      | Equity    | ROE   |
|--------------|-----------|-------|
| 2025-09-30  | $51.85B   | 11.16%  |
| 2025-06-30  | $48.99B   | 9.04%   |
| 2025-03-31  | $48.34B   | 10.51%  |
| 2024-12-31  | $46.31B   | 8.08%   |
| 2024-09-30  | $44.50B   | 7.09%   |

*   **Analysis:**  Revenue and profit margins have been consistently strong and increasing recently.  Equity is increasing, and Return on Equity (ROE) has improved significantly, indicating better profitability.

**7) Comprehensive Analysis**

*   **Underperformance vs. S&P 500:** MRK has significantly underperformed the S&P 500. The Alpha/Beta analysis reinforces this, showing negative Alpha values in recent periods.
*   **Mixed Signals:** While analyst consensus is positive and some recent news is encouraging, the RSI indicates an overbought condition, and the recent relative divergence change is minor, but positive. The hybrid signal recommends 100% investment, but the expected return is 0.0%, raising questions about the reliability of these indicators.
*   **Strong Financials:** Revenue, profit margins, equity, and ROE are all trending positively, indicating a healthy underlying business.
*   **Recommendation:** Due to the underperformance, overbought RSI, and high drawdown, a cautionary approach is warranted. While the analyst consensus and financial performance are positive, the technical indicators suggest a potential pullback. More research is needed to reconcile the contradictory signals. The recommendation of 100% investment by the Hybrid Signal is not completely convincing due to the zero Expected Return and should be further vetted.

In conclusion, while Merck demonstrates strong financial health and positive analyst sentiment, the underperformance relative to the market, technical indicators, and mixed news necessitate a cautious approach. A deeper dive into the reasons behind the underperformance and the reliability of the hybrid indicator would be beneficial before making an investment decision.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.